The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 02, 2020

Filed:

May. 31, 2017
Applicant:

The Trustees of Columbia University IN the City of New York, New York, NY (US);

Inventors:

Nicole Suciu-Foca, New York, NY (US);

George Vlad, Forest Hills, NY (US);

Chih-Chao Chang, Scarsdale, NY (US);

Zhuoru Liu, New York, NY (US);

Adriana Ioana Colovai, Dumont, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/68 (2017.01); A61K 39/00 (2006.01); G01N 33/574 (2006.01); C07K 16/28 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/30 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57492 (2013.01); A61K 47/6801 (2017.08); A61K 47/6849 (2017.08); A61K 47/6867 (2017.08); C07K 14/705 (2013.01); C07K 14/7051 (2013.01); C07K 14/70503 (2013.01); C07K 16/28 (2013.01); C07K 16/2803 (2013.01); C07K 16/3061 (2013.01); G01N 33/57426 (2013.01); G01N 33/57484 (2013.01); A61K 2039/505 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C07K 2319/40 (2013.01); C07K 2319/55 (2013.01); C07K 2319/74 (2013.01); G01N 2333/70503 (2013.01); G01N 2333/70596 (2013.01); G01N 2458/00 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present invention relates to methods of using the expression of ILTL3 ligand or ILT3 on certain types of cancer cells as a diagnostic tool. Methods are provided for treating ILT3-ligand expressing cancers, such as T-cell acute lymphoblastic leukemia (T-cell acute lymphoblastic leukemia), for example by administering ILT3, the extracellular domain of ILT3 or ILT3Fc conjugated to a cytotoxic agent to kill the targeted cancer cell. Other methods are provided for treating cancers that express ILT3 on their surface, such as monocytic forms of AML, for example by administering anti-ILT3 antibodies conjugated to a cytotoxic agent.


Find Patent Forward Citations

Loading…